Note: this journal is by subscription ($$$) for full access, the actual abstracts via this indexed list are not available - titles of presentations only - abstracts either have been previously published or to come
"In our own ovarian cancer
patient communities and over the long term, as survivours/family
caregivers, many of us have learned to question media articles and
abstracts. The SGO published a statement regarding the GOG 218 study
shortly after the media events.
In addition, on June 5th in Chicago on
a separate ovarian cancer seminar the issue of the new finding of GOG
218 were discussed. The over-riding bottom line is that Avastin is not
the panacea for all that ails ovarian cancer women and should be used
very selectively. On which patients is of primary interest (obviously).
The issue at stake for ovarian cancer women is that no new treatments
in the past 2 decades have shown any improvements over the standard and
current first line therapy of Taxol and Carboplatin.
No matter how bad it gets (QOL) and it does get very 'bad', ovarian
cancer women want to live and will suffer much to do so. We need to
understand this mindset while at the same time considering first most
patient safety and always acknowledging the 'hype'.
There is a duty for all those who care for ovarian cancer women to be informed.
Twitter, blogs, facebook and social media help also to educate patients on these issues - we hope."
search terms: "ovarian cancer' (note some duplication/non relevance)
The abstracts can be search a variety of ways: eg. gynecologic cancer, brca, etc...